Latest Breaking News On - Virios therapeutics inc - Page 8 : comparemela.com

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 - Virios Therapeutics (NASDAQ:VIRI)

ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat

Exchange commissionVirios therapeutics incVirios therapeuticsTherapeutics conferencePatent cooperation treatySecurities litigation reform actVirios therapeuticAnnual report

Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday s Mid-Day Session - Arcellx (NASDAQ:ACLX), Acurx Pharmaceuticals (NASDAQ:ACXP)

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.

United statesSan franciscoLumiradx limitedRegal rexnord corporationAlbemarle corporationHyzon motors incArcellx incAcurx pharmaceuticals incInari medical incDariohealth corpEnvista holdings corporationOmnicell incCrocs incMarkel group incSolaredge technologies incRuger company inc

McCollum Christoferson Group LLC Makes New Investment in Virios Therapeutics, Inc (NASDAQ:VIRI)

McCollum Christoferson Group LLC acquired a new stake in Virios Therapeutics, Inc. (NASDAQ:VIRI – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 30,700 shares of the company’s stock, valued at approximately $42,000. A number of other hedge funds […]

Gregory scott duncanRenaissance technologiesMccollum christoferson groupExchange commissionVanguard group incVirios therapeutics incSusquehanna international groupEnvestnet asset management incVirios therapeutics company profileSecurities exchange commissionVirios therapeuticsFree reportInternational groupAsset managementGet free reportScott duncan

Virios Therapeutics, Inc (NASDAQ:VIRI) Short Interest Down 33 4% in September

Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 278,500 shares, a decline of 33.4% from the September 15th total of 418,400 shares. Based on an average daily volume of 546,700 shares, […]

Gregory scott duncanGeode capital managementVirios therapeutics incVanguard group incMccollum christoferson groupRenaissance technologiesVirios therapeuticsGet free reportScott duncanCollum christoferson groupCapital managementStreet corpVirios therapeutics dailyNasdaq viri

Virios Therapeutics, Inc (NASDAQ:VIRI) Short Interest Down 33 4% in September

Virios Therapeutics, Inc (NASDAQ:VIRI) Short Interest Down 33 4% in September
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

Gregory scott duncanRenaissance technologiesVirios therapeutics incSusquehanna international groupGeode capital managementEnvestnet asset management incVanguard group incVirios therapeuticsGet free reportScott duncanInternational groupCapital managementEnvestnet asset managementAsset managementVirios therapeutics daily